At a glance
- Originator Sanofi-Synthelabo
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 30 Jan 1997 No-Development-Reported for Epilepsy in France (Unknown route)
- 05 Dec 1994 Phase-I clinical trials for Epilepsy in France (Unknown route)